Key findings in cancer biomarker expression highlighted on 2011 annual meeting of the American Association for cancer research

Current article ratings:
Patients / public:healthcare Prof:
This week presents CARIS life sciences, Inc., a leading Biosciences companies focused on allows precise and personalized vary by the highest quality pathology, molecular profiling and blood-based diagnostic services, clinical data, anatomic healthcare the possible diagnosis impact new biomarker profile in the fight against breast cancer checks. Further support these results the diagnosis value of the treatment of cancer based unique genetic makeup personalize to a tumour. The data comes ™ profiling cancer patients on the CARIS goal now evidence-based molecular profiling service, which examines a patient tumor and offers an individual tumor-specific biomarker analysis, who then published world's most prestigious cancer researchers with treatment of the data is matched.

A summary of each AACR poster presented the following:

"Correlation of HER2 expression of IHC, DNA Microarray, and fish in breast cancer," highlighted that protein expression of IHC is robust and low-cost way to test, HER2 expression if carried out per ASCO/CAP guidelines and correlated well with the amplification of the FALLOUT from fish. The study also showed that not clearly HER2-IHC and fish can results from microarray analysis due to poor inter assay agreement will be resolved. HER2 over expression occurs in about 15-20% of patients with breast cancer and associated with aggressive disease and reduced survive.

"Distribution of hormone receptors (estrogen receptor, progesterone receptor and androgen receptor) in epithelial cancers," has shown that hormone receptors often are expressed in cancers outside the chest, which deserves the inclusion of therapeutic strategies with hormone therapy in these tumors. The frequency of the hormone receptor expression in both expected and unexpected tumor types in evaluating new therapies, forecast determination and review the result of patients on endocrine therapy may be useful.

"The CARIS goal now molecular profiling service requires extraordinary resources to promote the current understanding of the different biomarkers and the potential role of molecular diagnostics in cancer therapy,", said Dr. Raheela Ashfaq, Medical Director of the oncologic pathology and primary author of two studies. "These efforts are crucial to the most relevant and effective information for doctors and patients in selecting the most effective cancer treatments." "For this purpose, we are confident that the results which we presented at the recently completed AACR Conference are new therapeutic options for the treatment of aggressive forms of cancer."

The CARIS goal now, molecular profiling service information from the individual tumor genetic profile with data in the almost 100,000 matches, published team verified clinical studies of CARIS evidence. CARIS goal now offers a simple report that specifies which bio biologic available chemo, and hormone therapies are most effective and those that are probably invalid. Now profiling service created CARIS goal last year as the world's most comprehensive and actionable tumor with almost 20,000 patients previously profiled.

Source:
CARIS life sciences